Skip to main content

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.21
+4.35 (2.12%)
AAPL  261.48
+0.90 (0.35%)
AMD  202.15
-1.22 (-0.60%)
BAC  52.88
+0.11 (0.21%)
GOOG  310.85
+7.29 (2.40%)
META  652.72
+7.94 (1.23%)
MSFT  397.70
-0.76 (-0.19%)
NVDA  187.73
-0.17 (-0.09%)
ORCL  152.61
-3.93 (-2.51%)
TSLA  410.26
-1.45 (-0.35%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.